Presentation
2.5g in 50mL (50mg/mL) vial
Keep Refrigerated
Role
Rapid reversal of anticoagulant effects of dabigatran in life-threatening or uncontrolled bleeding or to facilitate surgery.
Idarucizumab is a humanised monoclonal antibody fragment (Fab) that binds with dabigatran and its metabolites to form a stable inactive complex, reversing their anticoagulant effect.
Dose
5g (2 x 2.5g vials) IV as two consecutive boluses over 5 mins
Stocking recommendations
| Tertiary centre | Regional centre | Rural centre | Remote centre |
|---|---|---|---|
| 2 vials | 0-2 vials | 0 vials | 0 vials |
Rationale
The recommendations reflect a pragmatic approach to antidote stocking.
Disclaimer
Fact sheet developed by Queensland Poisons Information Centre.
This fact sheet is about the use of these antidotes in Australia, and may not apply to other countries. Children’s Health Queensland Hospital and Health Service cannot be held responsible for the accuracy of information, omissions of information, or any actions that may be taken as a consequence of reading this fact sheet.
Last updated: July 2023